Old Web
English
Sign In
Acemap
>
authorDetail
>
Musa Mutyaba
Musa Mutyaba
Axitinib
Vascular endothelial growth factor
Medicine
Tolerability
Oncology
3
Papers
18
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The DART Study: Results from the dose-escalation and expansion cohorts evaluating the combination of dalantercept plus axitinib in advanced renal cell carcinoma
2017
Clinical Cancer Research
Martin H. Voss
Rupal S. Bhatt
Elizabeth R. Plimack
Brian I. Rini
Robert S. Alter
J. Thaddeus-Beck
Dawn Wilson
Xiaosha Zhang
Musa Mutyaba
Chad Glasser
Kenneth M. Attie
Matthew L. Sherman
Shuchi Sumant Pandya
Michael B. Atkins
Show All
Source
Cite
Save
Citations (16)
The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC).
2015
Journal of Clinical Oncology
Martin H. Voss
Elizabeth R. Plimack
Brian I. Rini
Michael B. Atkins
Robert Alter
Rupal S. Bhatt
J. Thaddeus Beck
Musa Mutyaba
Kristen M. Pappas
Dawn Wilson
Xiaosha Zhang
Matthew L. Sherman
Shuchi Sumant Pandya
Show All
Source
Cite
Save
Citations (2)
The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC).
2015
Journal of Clinical Oncology
Martin H. Voss
Elizabeth R. Plimack
Brian I. Rini
Michael B. Atkins
Robert Alter
Rupal S. Bhatt
J. Thaddeus Beck
Musa Mutyaba
Kristen M. Pappas
Dawn Wilson
Xiaosha Zhang
Matthew L. Sherman
Shuchi Sumant Pandya
Show All
Source
Cite
Save
Citations (0)
1